The Levels of Tumor Necrosis Factor-Alpha and Interleukin-6 in Patients with Isolated Coronary Artery Ectasia. (11th May 2009)

• Record Type: Journal Article
• Authors: Aydin, Mustafa; Tekin, Ishak Ozel; Dogan, Sait Mesut; Yildirim, Nesligul; Arasli, Mehmet; Sayin, Muhammet Rasit; Aktop, Ziyaettin
• Other Names: Campbell Charles Larry Academic Editor.
• Is Part Of: Mediators of inflammation. Volume 2009(2009)
• Publication Date: 2009-05-11
• Subjects: Inflammation -- Mediators -- Periodicals; Biological response modifiers -- Periodicals; Inflammation (Pathologie) -- Médiateurs; Immunomodulateurs; Biological response modifiers; Inflammation -- Mediators; Immunology; Autacoids; Immunologic Factors; Cell Adhesion Molecules; Cell Communication; Cytokines; Inflammation; Periodicals; Electronic journals; 616.0473
• DOI: 10.1155/2009/106145
• Languages: English
• ISSNs: 0962-9351

Abstract

Abstract : Background/Aim . Coronary artery ectasia (CAE) is considered as a variant of atherosclerosis. Tumor necrosis factor-alpha (TNF-α ) and interleukin-6 (IL-6) are among the sensitive markers of systemic inflammation. The aim of this study was to evaluate the plasma levels of the cytokines; TNF-α and IL-6 in CAE patients. Methods . Plasma concentrations of TNF-α and IL-6 were measured in 36 patients with CAE (28 males, mean age:58.2 ± 12 years), and results were compared with age and sex-matched controls (n = 32 ) without coronary artery ectasia. TNF-α and IL-6 concentrations in blood were assesed by enzyme-linked immunosorbent assay (ELISA). Results . Baseline characteristics of the two groups were similar. TNF-α and IL-6 levels were significantly higher in CAE group than controls (15.6 ± 11.2 pg/mL versus7.8 ± 3.7 pg/mL, P < .001, and17.2 ± 12.6 versus7.6 ± 2.1 P < .0001, resp.). Conclusion . CAE patients showed increases in TNF-α and IL-6 levels compared to the controls. This study provides evidence for alterations in the proinflamatory cytokines which suggest the involvement of the immune system in the pathophysiology of CAE. Further placebo-controlled studies are needed to evaluate the clinical significance of this increase in TNF-α and IL-6 levels.